Skip to main content

Health condition · Clinically reviewed

Non-Hodgkin lymphoma, a spectrum from indolent to aggressive — R-CHOP to CAR-T.

A heterogeneous group of blood cancers arising from B or T cells. Modern treatment ranges from watchful waiting for indolent lymphomas to R-CHOP, targeted therapy and CAR-T for aggressive and relapsed disease.

Jump to treatment See red-flag symptoms
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced, not summarised

    Every claim is checked against NICE, BSH or a peer-reviewed source you can see at the end.

  • 03

    Updated for 2026

    Reflects current UK guidance on R-CHOP, bispecific antibodies and CAR-T cell therapy.

Key facts

Non-Hodgkin lymphoma at a glance.

The essentials, in plain English — what it is, the main subtypes, how it’s diagnosed in the UK today, and how treatment is chosen.

  • What it is

    A heterogeneous group of blood cancers arising from B or T lymphocytes.

  • Most common aggressive

    Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive subtype.

  • Most common indolent

    Follicular lymphoma is the most common indolent (slow-growing) subtype.

  • How it is diagnosed

    Lymph node biopsy with immunohistochemistry and molecular profiling are essential.

  • First-line for DLBCL

    R-CHOP chemo-immunotherapy remains the standard of care for DLBCL.

  • Refractory disease

    CAR-T cell therapy is offered for refractory or relapsed aggressive lymphoma.

Why this guide matters

Not one disease — a family of very different lymphomas.

NHL covers dozens of subtypes with very different biology and treatment. Getting the subtype right is what makes the treatment right.

  • Indolent vs aggressive matters

    Slow-growing follicular lymphoma is often watched; aggressive DLBCL needs treatment now — the labels drive everything.

  • Excisional biopsy is essential

    A whole node — not just a needle sample — is needed to see architecture and pin down the exact subtype.

  • CAR-T has changed the endgame

    Refractory and relapsed aggressive B-cell lymphomas now have a curative option many patients did not have before.

How the diagnosis is made

From first lump to a clear plan.

The pathway UK haemato-oncology teams follow, in order — so you know what to expect and why each step matters.

  1. 01

    Assessing

    Symptom + B-symptom review

    A careful history — painless lymphadenopathy, fever, drenching night sweats, unexplained weight loss and fatigue.

  2. 02

    Assessing

    Excisional lymph node biopsy

    A whole enlarged node is removed for architecture — a needle core is usually not enough for lymphoma diagnosis.

  3. 03

    Assessing

    FBC, LDH, LFT, HIV, HepB/C

    Baseline blood tests including lactate dehydrogenase, liver function and viral screening before treatment.

  4. 04

    Confirming

    PET-CT (Deauville scoring)

    Whole-body PET-CT stages the disease and gives a Deauville score used to guide and monitor treatment.

  5. 05

    Confirming

    Bone marrow biopsy

    A trephine biopsy is used in specific subtypes and staging scenarios when PET-CT is not conclusive.

  6. 06

    Planning

    Molecular / cytogenetic profiling

    Immunohistochemistry, FISH and molecular studies (MYC, BCL2, BCL6) refine subtype and prognosis.

  7. 07

    Planning

    Haemato-oncology MDT

    A specialist multi-disciplinary team decides subtype-specific treatment — from watchful waiting to CAR-T.

Typical timeline: 2–4 weeks from biopsy to a treatment plan.

Symptoms

What non-Hodgkin lymphoma actually shows up as.

Painless lymphadenopathy is the classic sign. B symptoms — fever, drenching night sweats and weight loss — matter for staging and prognosis.

  • Painless lymphadenopathy

    Persistent, painless swelling of neck, axillary or groin lymph nodes over weeks — the classic first sign.

  • B symptoms

    Fever above 38°C, drenching night sweats and unexplained weight loss of more than 10% over six months.

  • Fatigue

    Marked, persistent tiredness that does not resolve with rest — often present at diagnosis.

  • Recurrent infections

    Frequent or unusually severe infections can reflect immune dysfunction from the lymphoma itself.

  • Pruritus

    Generalised itching without a rash can be a systemic feature of lymphoma.

  • Splenomegaly / hepatomegaly

    An enlarged spleen or liver may be found on examination or imaging.

  • Extranodal disease

    Lymphoma can involve the gut, skin, CNS, bone or testis — presenting with organ-specific symptoms.

  • Red flag

    Airway compression or SVC obstruction, and spinal cord compression — call 999 immediately.

Treatment

How non-Hodgkin lymphoma is treated in the UK.

Treatment is chosen by subtype, stage and fitness — from watchful waiting for indolent disease, to chemo-immunotherapy, bispecifics and CAR-T for aggressive and relapsed lymphoma.

  • Watchful waiting (indolent)

    For asymptomatic low-tumour-burden follicular and other indolent lymphomas — treat only when needed.

  • Rituximab monotherapy

    Anti-CD20 antibody used alone in selected indolent disease and as maintenance therapy.

  • R-CHOP (DLBCL first-line)

    Rituximab with cyclophosphamide, doxorubicin, vincristine and prednisolone — the standard for DLBCL.

  • Polatuzumab vedotin + R-CHP (Pola-R-CHP)

    Antibody-drug conjugate combination — a modern first-line option for higher-risk DLBCL.

  • R-Bendamustine (follicular)

    Rituximab with bendamustine — effective and well-tolerated in first-line follicular lymphoma.

  • Bispecific antibodies

    Glofitamab and epcoritamab engage T cells against CD20+ lymphoma cells — used in relapsed disease.

  • CAR-T cell therapy

    Axi-cel, tisa-cel and liso-cel — engineered T cells for refractory or relapsed aggressive lymphoma.

  • Radiotherapy

    Involved-site radiotherapy for localised disease, symptom control and consolidation after chemotherapy.

What this guide is based on

The sources behind every number on this page.

UK and European guidance, specialist society standards and patient-organisation resources, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your GP or haemato-oncology team knows your history and can tell you which parts apply to you.

  • National Institute for Health and Care Excellence (NICE). Non-Hodgkin’s lymphoma: diagnosis and management (NG52).

  • British Society for Haematology. Guidelines on the management of non-Hodgkin lymphoma.

  • Lymphoma Action. Patient information and treatment resources.

  • European Society for Medical Oncology (ESMO). Clinical practice guidelines for non-Hodgkin lymphoma.

Red flags

When non-Hodgkin lymphoma becomes an emergency.

Lymphoma treatment is largely outpatient — but there are specific situations, on and off treatment, where you should act today.

  • Superior vena cava obstruction

    Facial swelling, breathlessness and distended neck veins from a mediastinal mass — same-day assessment.

  • Spinal cord compression

    New back pain with leg weakness, numbness or bladder/bowel change — call 999 or attend A&E immediately.

  • Tumour lysis syndrome

    High potassium, phosphate and urate after starting treatment — needs urgent bloods and intravenous fluids.

  • Neutropenic sepsis

    Fever above 38°C during chemotherapy — attend A&E for intravenous antibiotics within one hour.

  • CAR-T cytokine release syndrome

    Fever, low blood pressure and hypoxia after CAR-T infusion — treated with tocilizumab in a specialist centre.

  • Immune effector cell-associated neurotoxicity

    ICANS — confusion, tremor or seizures after CAR-T — needs urgent neurological review.

  • Post-transplant care

    Fever, bleeding, graft-versus-host symptoms or organ dysfunction after stem cell transplant — contact the transplant team.

  • CNS lymphoma progression

    New headache, cranial nerve signs or altered consciousness — urgent MRI and lumbar puncture.

  • Palliative-stage crisis

    Uncontrolled pain, breathlessness or bleeding in advanced disease — contact the specialist palliative team.

Living with it

A long-term journey, with structured support.

Four things that make the biggest difference day to day — response monitoring, infection safety, fertility and structured follow-up.

A quiet reminder

Ask about fertility early.

Sperm banking and oocyte preservation are best organised before the first cycle of chemotherapy — bring it up at the first appointment.

  1. 01 Monitoring

    PET-CT and Deauville scoring

    Response is measured with PET-CT using the five-point Deauville score — a low score means good response.

  2. 02 Side effects

    Neutropenia and infection

    Chemotherapy lowers immunity — recognise fever early, keep an infection-avoidance plan and know when to call.

  3. 03 Fertility

    Fertility before treatment

    Chemotherapy can affect fertility — ask about sperm banking or oocyte preservation before starting.

  4. 04 Reviews

    Long-term follow-up

    Structured haemato-oncology follow-up watches for late effects, second cancers and cardiac toxicity.

Frequently asked

Everything we get asked about non-Hodgkin lymphoma.

Quick answers on subtypes, biopsy, R-CHOP, CAR-T and when to worry.

  • What is non-Hodgkin lymphoma?

    Non-Hodgkin lymphoma (NHL) is a heterogeneous group of blood cancers arising from B or T lymphocytes. It ranges from indolent (slow-growing) subtypes such as follicular lymphoma to aggressive subtypes such as diffuse large B-cell lymphoma (DLBCL).

  • How is non-Hodgkin lymphoma diagnosed?

    Diagnosis requires an excisional lymph node biopsy — removing a whole node for architecture and immunohistochemistry. Molecular and cytogenetic profiling refine the subtype. Staging is by PET-CT with Deauville scoring, sometimes with bone marrow biopsy.

  • What is R-CHOP?

    R-CHOP is a chemo-immunotherapy combining rituximab (an anti-CD20 antibody) with cyclophosphamide, doxorubicin, vincristine and prednisolone. It remains the standard first-line treatment for diffuse large B-cell lymphoma (DLBCL).

  • What is CAR-T cell therapy?

    CAR-T therapy re-engineers a patient’s own T cells to recognise and kill lymphoma cells. Axi-cel, tisa-cel and liso-cel are licensed for refractory or relapsed aggressive B-cell lymphoma. It is delivered in specialist centres and can cause cytokine release syndrome and neurotoxicity (ICANS).

  • Do all lymphomas need treating immediately?

    No. Many indolent lymphomas — including low-tumour-burden follicular lymphoma — are safely managed with watchful waiting until symptoms or signs of progression appear. Aggressive lymphomas such as DLBCL do need prompt treatment.

  • When should I worry about symptoms?

    Persistent painless lymphadenopathy, fever, drenching night sweats or unexplained weight loss deserve urgent review. Facial swelling with breathlessness, or new leg weakness with back pain — call 999 to exclude SVC obstruction or cord compression.

Related content

Keep reading.

WhatsApp Call us
Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

Confidential. We respond within one working day.